Evidence map›Paper›PMID 39075383›Full record

ArticleBMC infectious diseases2024

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.

Frank Mulindwa, Jean-Marc Schwarz, Nele Brusselaers, Martin Nabwana, Robert Bollinger, Allan Buzibye, Willington Amutuhaire, George Yendewa, Eva Laker Agnes Odongpiny, Ronald Kiguba and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Frank MulindwaCapacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda. fmulindwa@idi.co.ug.
Jean-Marc SchwarzSchool of Medicine, University of California San Francisco, San Francisco, USA.
Nele BrusselaersGlobal Health Institute, Antwerp University, Antwerp, Belgium.
Martin NabwanaMakerere University Johns Hopkins University Research Collaboration, Kampala, Uganda.
Robert BollingerSchool of Medicine, Johns Hopkins University, Baltimore, USA.
Allan BuzibyeCapacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda.
Willington AmutuhaireDepartment of Internal Medicine, Case Western Reserve University, Cleveland, OH, USA.
George YendewaDepartment of Internal Medicine, Case Western Reserve University, Cleveland, OH, USA.
Eva Laker Agnes OdongpinyCapacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda.
Ronald KigubaDepartment of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda.
Barbara CastelnuovoCapacity Building Program, Makerere University Infectious Diseases Institute, Kampala, Uganda.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
University of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7M
HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
FIC NIH HHS D43 TW009343FIC NIH HHS D43 TW009771Fogarty International Center of the National Institutes of Health, Infectious Diseases Institute 'HIV and coinfections' D43TW009771National Institutes of Health, UCSF-Gladstone Center for AIDS Research P30AI027763NIAID NIH HHS P30 AI027763NIH-Fogarty University of California (UCSF) global health fellowship program 2D43TW009343-06
6 · The paper itself

Abstract

backgroundThe Uganda ministry of Health recommends frequent blood glucose monitoring for the first six months on dolutegravir, in people with HIV (PWH) having pre-diabetes mellitus (pre-DM). We sought to determine if indeed PWH with pre-diabetes started on dolutegravir had worse blood glucose outcomes at 48 weeks compared to those with normal blood glucose.

methodsIn this matched cohort study, we compared 44 PWH with pre-DM and 88 PWH with normal blood glucose at baseline. The primary outcome was change in mean fasting blood glucose (FBG) from baseline to week 48 and 2-hour blood glucose (2hBG) from baseline to week 36 compared between the two groups.

resultsThere was significant increase in FBG in PWH with normal blood glucose (mean change in FBG(FBG): 3.9 mg/dl, 95% confidence interval (95% CI): (2.2, 5.7), p value (p) = < 0.0001) and decrease in those with pre-DM (FBG: -6.1 mg/dl, 95%CI (-9.1, -3.2), p = < 0.0001) at 48 weeks. 2hBG was significantly lower than at baseline in both groups with the magnitude of reduction larger in those with pre-DM at 12 weeks (adjusted differences in mean drop in 2hBG (a2hBG): -19.69 mg/dl, 95%CI (-30.19, -9.19), p = < 0.0001) and 36 weeks (a2hBG: -19.97 mg/dl, 95%CI (-30.56, -9.39), p = < 0.0001).

conclusionWe demonstrated that Ugandan ART naïve PWH with pre-diabetes at enrollment have consistent improvement in both fasting blood glucose and glucose tolerance over 48 weeks on dolutegravir. Intensified blood glucose monitoring of these patients in the first six months of dolutegravir may be unnecessary.

Indexed as

Blood GlucoseHeterocyclic Compounds, 3-RingHIV InfectionsOxazinesPiperazinesPrediabetic StatePyridonesAdultCohort StudiesDolutegravirEast African PeopleFemaleHIV Integrase InhibitorsHumansMaleMiddle AgedBlood GlucoseDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesBlood glucoseDiabetes mellitusDolutegravirIntegrase inhibitors

Identifiers

PMID39075383
PMCPMC11285129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.